NCT06690242 - MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

March 31, 2026

Conditions

Secondary Hyperparathyroidism (SHPT) in Subjects with Chronic Kidney Disease (CKD) on Hemodialysis

Interventions

DRUG

MT1013

MT1013 is a novel calcimimetic agent

DRUG

MT1013

MT1013 is a novel calcimimetic agent

DRUG

Etelcalcetide Hydrochloride

the already-marketed therapeutic agents

DRUG

Placebo

The measure does not contain the active ingredients

Trial Locations (1)

RECRUITING

First Affiliated Hospital College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

lead

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

INDUSTRY